XVIVO: In excellent shape with a few blemishes - Redeye

XVIVO delivers both improved Gross- and EBITDA margins and an overall organic growth of 42% (CER) which is very good by most comparisons. The Thoracic disposables buisness recorded sales below expectations in Q3 mostly as a result of the strong Q3 2022 and a strong Q2 in 2023. Thoracic gross margins improved by 4% to 85% in Q3. The outlook remains positive and the important US Heart study has started.

Länk till analysen i sin helhet: https://www.redeye.se/research/948999/xvivo-in-very-good-good-shape-with-a-few-blemishes?utm_source=finwire&utm_medium=RSS